tirzepatide vision loss risks in patients using popular GLP-1 medications raise concerns Mounjaro Eye Side Effects Lawsuit

Perkovic, V., et al

Tirzepatide works by activating GIP and GLP-1 receptors, two natural pathways involved in appetite regulation and metabolism

These side effects tend to be mild and subside as the body adjusts to the medication, usually within a few weeks

Here is a side-by-side comparison based on available trial data: Semaglutide 2.4 mg (Wegovy): 14.9% average weight loss over 68 weeks, GLP-1 receptor agonist only Tirzepatide 15 mg (Zepbound/Mounjaro): 20.9% average weight loss over 72 weeks, dual GLP-1 and GIP agonist Retatrutide 12 mg: 24.2% average weight loss over 48 weeks, triple GLP-1, GIP, and glucagon agonist What I found interesting in the data is that retatrutide appears to produce faster early weight loss than either semaglutide or tirzepatide